Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients

Inclusion Criteria for prostate cancer patients: * localised prostate cancer, histologically proven * Absence of metastases (M0) : normal bone scintigraphy * Absence of radiological lymph node invasion (N0). * Clinical Stage : T ≥ T1c-T2a and \< T3b Or T1b or c with PSA ≤ 10 ng/ml . Or T1b or c with Gleason ≥ 6 * PSA \< 30 ng/ml. * Signs and symptoms according to NCI/CTC v3.0 \< grade 2 * ECOG Performance status ≤ 1 * Absence of hip prothesis * Absence de endopenian stent * Patient aged \> 18 and \< 80 * Patient affiliated with social security * Written informed consent, dated and signed Exclusion Criteria for prostate cancer patients: * Antecedents of invasive cancer (unless if treated more than 5 years ago without evolution) except basocellular carcinoma * positive biopsy of seminal vesicle * PSA ≥ 30 ng/ml for two successive dosages * Previous pelvic irradiation * Previous radical prostatectomy for cancer * Patients with another systemic disease (cardiovascular, renal, hepatic, pulmonary embolism, etc.) non stabilised or generalised sclerodermitis. * Patients known to be HIV seropositive (no specific test is necessary for defining eligibility) * Known homozygote ATM (Ataxy telangiectasy) mutation * Impossibility for a correct follow up (for social family or geographical reasons) * Patients incapable of providing consent, protected majors, vulnerable persons * Patients participating in other clinical trials Inclusion Criteria for breast cancer patients: * Breast Conser…